POLYMYOSITIS

This study tests a new treatment for people with lupus, scleroderma, or certain muscle diseases. The treatment uses a patient's own immune cells, modified to find and attack faulty B cells that drive the disease. About 24 adults will receive the therapy after a short course of ch…

This study looks at the long-term safety of a medicine called dazukibart for people with dermatomyositis or polymyositis, which are rare diseases that cause muscle weakness and can affect daily activities. About 211 adults who completed a previous dazukibart study will receive th…

This early-stage study tests a new medicine, SAR448501/DR-0201, in adults with lupus or rheumatoid arthritis. The goal is to find safe and tolerable doses by checking side effects and how the drug works in the body. About 62 participants will receive multiple doses and be followe…

This study is building a large collection of health information and blood samples from 5,000 adults with rheumatic diseases like rheumatoid arthritis, lupus, and scleroderma. Researchers will use this data to find links between patient outcomes and biological markers. The goal is…

This study asks people with rare myositis diseases (like dermatomyositis or inclusion body myositis) and their caregivers what they think researchers should focus on. Through online surveys and forums, the goal is to create a list of patient-driven research priorities. The study …

This study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 adults and children with myositis, along with healthy volunteers, to track symptoms, immune system changes, and related health issues.…

This study looks at whether certain environmental exposures—like infections, stress, or sun exposure—are more common in people with anti-synthetase syndrome (a type of myositis with lung involvement) compared to other myositis patients and healthy volunteers. Researchers will col…